The introduction of an IDH2 R172K mutation, the main IDH2 mutation in gliomas, into C3H10T1/2 was previously shown to reduce the expression of the COL2A1 gene and gave rise to poorly differentiated sarcomas in xenograft models [34]. The gene discussed is IDH2; the disease is central nervous system cancer.